UMEM Research Studies

Study TitleStudy DatesSponsorStatusPrimary Investigator(s)Other Investigator(s)
REVVED UP 01/01/2021 to 02/01/2021 N/A Completed Gentry Wilkerson
Description:

An ED based survey of non-critically ill patients asking them questions that relate to the following domains: Where they get primary care (or any health care), current mask usage and availability, receptiveness to immunization with a COVID-19 vaccine, barriers and concerns about immunization with a COVID-19 vaccine.

Keywords:
SARS-CoV-2, COVID-19
COVID Home SpO2 05/18/2020 to 10/09/2020 N/A Completed Gentry Wilkerson
Angela Smedley
Christy Carter
Description:

A prospective, non blinded, non randomized trial conducted at the University of Maryland Medical Center Downtown Campus (UMMC) located in Baltimore, Maryland that aims to evaluate patient engagement in a program to monitor home pulse oximetry and development of symptoms for patients with or under investigation for infection with SARS-CoV-2. 

Keywords:
SARS-CoV-2, COVID-19, Pulse Oximetry, Pulse Oximeter
BLD-2660 05/04/2020 to 09/14/2020 Blade Therapeutics, Inc Completed Gentry Wilkerson
Description:

A Phase 2 randomized, double-blinded, placebo-controlled multicenter study designed to evaluate BLD-2660 as add-on to standard of care (SOC) therapy in hospitalized subjects with recently diagnosed COVID-19 compared to SOC treatment. The study will include a Screening period, a Treatment period, and a Follow-up period.

 


Clinicaltrials.gov ID: NCT04334460
Keywords:
SARS-CoV-2, COVID-19, Calpain, Calpain inhibitors
DIAMOND 01/01/2018 to 08/31/2020 Janssen Research & Development, LLC Terminated Gentry Wilkerson
Mike Winters
Description:

A multi-centered, double blinded clinical trial to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment in participants with Influenza A who are at risk of developing complications. 

 


Clinicaltrials.gov ID: NCT03381196
Keywords:
Influenza A, Upper Respiratory Tract infection, URI, Pimodivir
SAPPHIRE 01/01/2018 to 08/31/2020 Janssen Research & Development, LLC Terminated Gentry Wilkerson
Mike Winters
Description:

A multi-centered, double blinded clinical trial to evaluate the efficacy/safety of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment in hospitalized participants with Influenza A.


Clinicaltrials.gov ID: NCT03376321
Keywords:
Influenza A, Upper Respiratory Tract infection, URI, Pimodivir
COMPARE-VOE 04/01/2019 to - Duke University - NHLBI/NIH Recruiting Gentry Wilkerson
Sarah Dubbs
Description:

A phase III randomized single blinded study that aims to compare the two analgesic protocols recommended by the NHLBI for treating Vaso-occlusive episodes in the Emergency Department.


Clinicaltrials.gov ID: NCT03933397
Keywords:
Sickle Cell Disease, Vaso-occlusive episodes, Acute pain crisis, Opioid, Analgesia
CEPHEID 09/01/2018 to - Cepheid Recruiting Gentry Wilkerson
Description:

A prospective, nonblinded, randomized controlled trial that aims to assess whether an FDA-approved rapid turnaround test (RTAT) for Neisseria gonorrheae and Chlamydia trachomatis infections will lead to more appropriate antibiotic prescription in the emergency department. 


Clinicaltrials.gov ID: NCT03098394
Keywords:
Sexually Transmitted Disease, Sexually Transmitted Infection, STD, Gonorrhea, Chlamydia, Rapid Turnaround Test, Vaginal Discharge
Percutaneous Ultrasound Gastrostomy technique 08/01/2019 to - CoapTech Recruiting Gentry Wilkerson
Michael McCurdy
Daniel Haase
Kami Windsor
WanTsu Wendy Chang
Description:

A single-center, non-randomized, non-blinded feasibility study to evaluate the performance, safety and tolerability of the Percutaneous Ultrasound Gastrostomy (PUG) procedure that utilizes a novel device in conjunction with widely available ultrasound technology.


Clinicaltrials.gov ID: NCT03956277
Keywords:
Gastrostomy, Percutaneous Ultrasound Gastrostomy, PUG, Feeding tube
REGENERON 2067 10/01/2020 to - Regeneron Pharmaceuticals Recruiting Gentry Wilkerson
Description:

A randomized, double-blinded, placebo-controlled, adaptive phase 1/2/3 master protocol will assess the safety, tolerability, and efficacy of REGN10933+REGN10987 and REGN10989 in ambulatory patients with COVID-19. The multicenter conduct of this study will enable generalizable evidence of the safety, tolerability, and efficacy of these investigational mAbs for COVID-19.


Clinicaltrials.gov ID: NCT04425629
Keywords:
SARS-CoV-2, COVID-19, Regeneron, SPIKE, Anti-SPIKE, Monoclonal Antibody
Eli Lilly PYAB (BLAZE-1) 04/01/2021 to - Eli Lilly and Company Recruiting Gentry Wilkerson
Description:

This study aims to evaluate the impact of LY3819253 and LY3819253 in combination with LY3832479 on viral clearance and clinical outcomes in participants with mild to moderate COVID-19 illness. The data from this study will inform decisions for the clinical development of these neutralizing IgG1mAbs. 


Clinicaltrials.gov ID: NCT04427501
Keywords:
SARS-CoV-2, COVID-19, Monoclonal Antibody
Eli Lilly PYAH (BLAZE-4) 04/01/2021 to - Eli Lilly and Company Recruiting Gentry Wilkerson
Description:

The aim of the study is to evaluate the impact of LY3819253 alone, LY3853113 alone, LY3819253 + LY3832479, LY3853113+ LY3819253 + LY3832479, and LY3819253 + VIR7831 on viral clearance and clinical outcomes in participants with COVID-19 illness. 


Clinicaltrials.gov ID: NCT04634409
Keywords:
SARS-CoV-2, COVID-19, Monoclonal Antibody
Microparticle Levels in ACE-inhibitor Induced Angioedema 04/01/2021 to - N/A Recruiting Gentry Wilkerson
Stephen Thom
Description:

The overall goal of this study is to determine whether the levels of microparticles may be elevated in patients with angioedema that develops as a result of the use of the class of blood pressure medications, ACE inhibitors.

Keywords:
Angioedema, ACE, ACE-inhibitor, Microparticles